Contract Pharma Manufacturing editorial

1. NK Cell Therapies: How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach 4/24/2024

   We caught up with Chris Horan, Artiva Biotherapeutics' CTO, to discuss natural killer cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.

2. Improving Governance And Compliance With Knowledge Management 4/23/2024

   Knowledge management — it’s not just a soulless exercise. In the last part of his series, Hirsh helps bridge the gap between compliance and business needs.

3. Nothing To See Here! Just Big Pharma Investments In China 4/22/2024

   WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.

4. GMP Plant Uniform Lockers And Procedures: Best Practices 4/22/2024

   As the use of GMP plant uniforms has gained acceptance, locker room layouts have arisen across companies and sites. This article examines alternatives and optimized approaches.

5. A Deeper Look At What's Driving Dependence On Biotech Contract Manufacturers 4/19/2024

   Are you struggling to find CDMO capacity? Here are some of the drivers behind the contract manufacturing market's exponential growth.

6. CDMOs Pelted By Slings And Arrows 4/18/2024

   Chief Editor Louis Garguilo thought he was precipitating a frontal assault by canvassing the Outsourced Pharma Editorial Advisory Board with questions such as: When outsourcing development and manufacturing, what are the challenges, and where are your pain points? But before anyone claims “one-sided,” please read on.

7. What Time Is Best To Bring My CDMO On Board? 4/17/2024

   The answer might be sooner than you think and entail more transparency than you're used to.

8. A Good Feeling ($$) About Contract Manufacturing 4/15/2024

   Occasionally, we look at revenue numbers assigned to the collective activities we focus on at Outsourced Pharma: drug development and manufacturing outsourcing, and working with CDMOs. And we also can provide some pep talks, too.

9. You Want To Rein In China? Then Actually Do It 4/12/2024

   Chief Editor Louis Garguilo takes a hard look at proposed legislation H.R. 7085 - the BIOSECURE Act - and draws out some interesting angles and conclusions regarding the biopharma battle between the U.S. and China.

10. Cell Counting Is Growing More Important Amid Advanced Therapy’s Rise 4/12/2024

    You can't improve what you don't measure. This discussion explores advances in cell counting technology and the growing number of ways it aids the biotech industry and beyond.